Back to search results

CARE-Heme Registry for Older Adults with Blood Cancers

This study, called the CARE-Heme Registry, aims to create a collection of information about older adults (age 50 and above) who have blood cancers like Multiple Myeloma, Amyloidosis, or Plasma Cell Leukemia. The main goal is to understand how common frailty (weakness or being fragile) and other age-related health issues are in this group. Researchers also want to gather information to help plan future studies for these patients. You can join if you are 50 years or older and have a confirmed diagnosis of a blood cancer. The study is considered successful if the CARE-Heme Registry is established within five years. The current recruitment status is unclear.

Study design
This is an observational study, meaning researchers will collect information without giving any specific treatments. It plans to enroll 5000 participants.
What's involved
You will be asked to complete a questionnaire about your health and participate in physical tests, including a short physical performance battery and a hand grip test. These will be done at the start, and then repeated at 3 months, 6 months, and one year. A blood or saliva sample will also be requested once.
Compensation
Not stated in the trial record.
Follow-up
You will have follow-up assessments at 3 months, 6 months, and one year after your initial visit.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05556928

Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry

Recruiting
Not specifiedAges 50+Observational
University of Alabama at Birmingham
~5,000 participants
Updated 2025-12-08 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Create the CARE-Heme Registry
Measured over 5 years

Conditions

Multiple Myeloma
Amyloidosis
Plasma Cell Leukemia

Explore related trials

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAmyloidosisChronic Lymphocytic LeukemiaChronic Myeloid Leukemia, BCR-ABL1 PositiveHematologic NeoplasmHodgkin's GranulomaMultiple MyelomaMyelodysplastic SyndromeMyeloproliferative NeoplasmNon-Hodgkin LymphomaPlasma Cell LeukemiaWaldenstrom Macroglobulinemia

Where it's being run

1 sites across 1 states
Alabama1

Who to contact

Landon Martin, BS
[email protected]
(205) 638-2120
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients are ≥50 years of age.
Patients have a biopsy proven diagnosis of Hematologic Malignancy (Multiple Myeloma, AL Amyloidosis, Waldenstrom's Macrogloblunemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Myelodysplastic syndromes, Myeloproliferative Neoplasm, Acute/Chronic Myeloid Leukemia, Acute/Chronic Lymphoid Leukemia).
Patients have appointments at UAB including if they are an inpatient or other clinic locations.

Exclusion

Individuals who are \<50 years old.
Patients who do not read and/or speak English will not be eligible for this study as many of the questionnaires are not validated in other languages. No exclusions will be made based on gender, ethnicity or race.

What this trial measures

  • Create the CARE-Heme Registry5 years

    To establish and maintain a well-annotated registry (to be called the 'CARE-Heme' Registry) of adults ≥50 years of age with a hematologic malignancy to improve our understanding of this vulnerable population.